Literature DB >> 9038311

Deletion analysis of the Clostridium perfringens enterotoxin.

J F Kokai-Kun1, B A McClane.   

Abstract

To further our knowledge of the structure-function relationship and mechanism of action of the Clostridium perfringens enterotoxin (CPE), a series of recombinant CPE (rCPE) species containing N- and C-terminal CPE deletion fragments was constructed by recombinant DNA approaches. Each rCPE species was characterized for its ability to complete the first four early steps in the action of CPE, putatively ordered as specific binding, a postbinding physical change to bound CPE, large-complex formation, and induction of alterations in small-molecule membrane permeability. These studies demonstrated that (i) at least 44 amino acids can be removed from the N terminus of CPE without loss of cytotoxicity, (ii) removal of the first 53 amino acids from the N terminus of CPE produces a fragment that appears to be noncytotoxic because it cannot undergo the post-binding physical change step in CPE action, (iii) removal of as few as five amino acids from the C terminus of CPE produces a noncytotoxic fragment lacking receptor binding activity, and (iv) a fragment lacking the first 44 N-terminal amino acids of native CPE formed twice as much large complex and was twice as cytotoxic as native CPE. From these structure-function results, it appears that the minimum-size cytotoxic CPE fragment comprises approximately residues 45 to 319 of native CPE. Results from these deletion fragment studies have also contributed to our understanding of CPE action by (i) independently supporting previous suggestions that binding, the postbinding physical change step, and large-complex formation represent important steps in CPE cytotoxicity and (ii) providing independent evidence confirming the putative sequential order of these early events in CPE action.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9038311      PMCID: PMC175083     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Mapping of functional regions of Clostridium perfringens type A enterotoxin.

Authors:  P C Hanna; E U Wieckowski; T A Mietzner; B A McClane
Journal:  Infect Immun       Date:  1992-05       Impact factor: 3.441

2.  Localization of the receptor-binding region of Clostridium perfringens enterotoxin utilizing cloned toxin fragments and synthetic peptides. The 30 C-terminal amino acids define a functional binding region.

Authors:  P C Hanna; T A Mietzner; G K Schoolnik; B A McClane
Journal:  J Biol Chem       Date:  1991-06-15       Impact factor: 5.157

3.  A recombinant C-terminal toxin fragment provides evidence that membrane insertion is important for Clostridium perfringens enterotoxin cytotoxicity.

Authors:  P C Hanna; B A McClane
Journal:  Mol Microbiol       Date:  1991-01       Impact factor: 3.501

4.  Evidence that alterations in small molecule permeability are involved in the Clostridium perfringens type A enterotoxin-induced inhibition of macromolecular synthesis in Vero cells.

Authors:  K I Hulkower; A P Wnek; B A McClane
Journal:  J Cell Physiol       Date:  1989-09       Impact factor: 6.384

5.  Molecular cloning of the 3' half of the Clostridium perfringens enterotoxin gene and demonstration that this region encodes receptor-binding activity.

Authors:  P C Hanna; A P Wnek; B A McClane
Journal:  J Bacteriol       Date:  1989-12       Impact factor: 3.490

Review 6.  Clostridium perfringens enterotoxin acts by producing small molecule permeability alterations in plasma membranes.

Authors:  B A McClane
Journal:  Toxicology       Date:  1994-02-28       Impact factor: 4.221

7.  Cloning, nucleotide sequencing, and expression of the Clostridium perfringens enterotoxin gene in Escherichia coli.

Authors:  J R Czeczulin; P C Hanna; B A McClane
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

8.  Evidence that an approximately 50-kDa mammalian plasma membrane protein with receptor-like properties mediates the amphiphilicity of specifically bound Clostridium perfringens enterotoxin.

Authors:  E U Wieckowski; A P Wnek; B A McClane
Journal:  J Biol Chem       Date:  1994-04-08       Impact factor: 5.157

9.  Organization of the botulinum neurotoxin C1 gene and its associated non-toxic protein genes in Clostridium botulinum C 468.

Authors:  D Hauser; M W Eklund; P Boquet; M R Popoff
Journal:  Mol Gen Genet       Date:  1994-06-15

10.  Comparison of Western immunoblots and gene detection assays for identification of potentially enterotoxigenic isolates of Clostridium perfringens.

Authors:  J F Kokai-Kun; J G Songer; J R Czeczulin; F Chen; B A McClane
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

View more
  28 in total

1.  Mechanism of Clostridium perfringens enterotoxin interaction with claudin-3/-4 protein suggests structural modifications of the toxin to target specific claudins.

Authors:  Anna Veshnyakova; Jörg Piontek; Jonas Protze; Negar Waziri; Ivonne Heise; Gerd Krause
Journal:  J Biol Chem       Date:  2011-11-28       Impact factor: 5.157

2.  Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin.

Authors:  Babak Litkouhi; Joseph Kwong; Chun-Min Lo; James G Smedley; Bruce A McClane; Margarita Aponte; Zhijian Gao; Jennifer L Sarno; Jennifer Hinners; William R Welch; Ross S Berkowitz; Samuel C Mok; Elizabeth I O Garner
Journal:  Neoplasia       Date:  2007-04       Impact factor: 5.715

3.  Noncytotoxic Clostridium perfringens enterotoxin (CPE) variants localize CPE intestinal binding and demonstrate a relationship between CPE-induced cytotoxicity and enterotoxicity.

Authors:  James G Smedley; Juliann Saputo; Jacquelyn C Parker; Mariano E Fernandez-Miyakawa; Susan L Robertson; Bruce A McClane; Francisco A Uzal
Journal:  Infect Immun       Date:  2008-05-27       Impact factor: 3.441

4.  Directed structural modification of Clostridium perfringens enterotoxin to enhance binding to claudin-5.

Authors:  Jonas Protze; Miriam Eichner; Anna Piontek; Stefan Dinter; Jan Rossa; Kinga Grażyna Blecharz; Peter Vajkoczy; Joerg Piontek; Gerd Krause
Journal:  Cell Mol Life Sci       Date:  2014-10-24       Impact factor: 9.261

5.  C terminus of Clostridium perfringens enterotoxin downregulates CLDN4 and sensitizes ovarian cancer cells to Taxol and Carboplatin.

Authors:  Zhijian Gao; Xiaoyin Xu; Bruce McClane; Qing Zeng; Babak Litkouhi; William R Welch; Ross S Berkowitz; Samuel C Mok; Elizabeth I O Garner
Journal:  Clin Cancer Res       Date:  2010-12-01       Impact factor: 12.531

6.  Identification of a Clostridium perfringens enterotoxin region required for large complex formation and cytotoxicity by random mutagenesis.

Authors:  J F Kokai-Kun; K Benton; E U Wieckowski; B A McClane
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

7.  Characterization of membrane-associated Clostridium perfringens enterotoxin following pronase treatment.

Authors:  E U Wieckowski; J F Kokai-Kun; B A McClane
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

8.  Clostridium perfringens enterotoxin interacts with claudins via electrostatic attraction.

Authors:  Jun Kimura; Hiroyuki Abe; Shigeki Kamitani; Hirono Toshima; Aya Fukui; Masami Miyake; Yoichi Kamata; Yoshiko Sugita-Konishi; Shigeki Yamamoto; Yasuhiko Horiguchi
Journal:  J Biol Chem       Date:  2009-11-10       Impact factor: 5.157

9.  Cysteine-scanning mutagenesis supports the importance of Clostridium perfringens enterotoxin amino acids 80 to 106 for membrane insertion and pore formation.

Authors:  Jianwu Chen; James R Theoret; Archana Shrestha; James G Smedley; Bruce A McClane
Journal:  Infect Immun       Date:  2012-09-10       Impact factor: 3.441

Review 10.  The interaction of Clostridium perfringens enterotoxin with receptor claudins.

Authors:  Archana Shrestha; Francisco A Uzal; Bruce A McClane
Journal:  Anaerobe       Date:  2016-04-16       Impact factor: 3.331

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.